PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555495
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1555495
Continuous Bioprocessing Market size was valued at USD 214.6 Million in 2023, expanding at a CAGR of 21.40% from 2024 to 2032.
The integrated continuous unit processes used in continuous bioprocessing do not have intermediary holding tanks; instead, the product flows continuously through them and into containers. Extremely intense processing with brief downtimes is a characteristic of continuous unit operations. A multi-column chromatography system, a perfusion bioreactor, and multi-column intermediate purification are components of an end-to-end bioprocess. For continuous biopharmaceutical manufacturing, some pharmaceutical and biopharmaceutical producers use a hybrid strategy where just the upstream or downstream process is continuous.
Continuous Bioprocessing Market- Market Dynamics
Increased Demand for Biopharmaceuticals to Propel Market Growth
Biopharmaceuticals are in greater demand because of their high activity and selectivity, low side effects, and capacity to target particular molecules. The treatment of immune-mediated inflammatory diseases (IMIDs), such as cancer, inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), is becoming more and more dependent on biopharmaceuticals. The steady rise also aids the market's expansion in biopharmaceutical approvals. The U.S. FDA reports that of all the medications authorized in 2022, 15 were biologics, as opposed to 13 in 2020. Additionally, implementing continuous manufacturing techniques in commercial production lowers manufacturing costs. It increases productivity, which lowers the cost of biopharmaceutical products, increases accessibility to medications, and enhances the standard of care. Biopharmaceutical manufacturing is changing as a result of continuous bioprocessing. Continuous bioprocessing is becoming more widely used in the production of biopharmaceuticals due to its advantages over traditional flow manufacturing. These advantages include enhanced process design flexibility, improved process economics, ease of scale-up, and quick development timelines.
Continuous Bioprocessing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 21.40% over the forecast period (2024-2032)
Based on product segmentation, the Filtration Systems and Devices category was predicted to show maximum market share in the year 2023
Based on the scale of operation segmentation, the commercial operations category was the leading segment in 2023
Based on application segmentation, the Monoclonal Antibodies category was the leading segment in 2023
Based on end-user segmentation, the Pharmaceutical and Biotechnology Companies category was the leading segment in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Continuous Bioprocessing Market is segmented based on Product, Scale of Operation, Process, Application, End-user and Region.
The market is divided into two categories based on scale of operation: Commercial Operations and Clinical Operations. The commercial operations category dominates the market. The strong demand for biopharmaceutical goods, such as vaccines, cell and gene therapies, monoclonal antibodies, and other biologics, helps the commercial sector. Additionally, the need for sophisticated biopharmaceutical medicines is expanding as the world's population ages and the prevalence of chronic diseases rises, which is propelling the commercial segment's expansion even further. Furthermore, compared to conventional batch processing techniques, continuous bioprocessing provides benefits like increased productivity and improved process control, which makes it a good fit for large-scale commercial production.
The market is divided into two categories based on Process: Downstream Bioprocess and Upstream Bioprocess. The downstream bioprocess category dominates the market and is likely to maintain its dominance during the forecast period. The segment's rise is ascribed to its vital function in fulfilling regulatory standards, achieving product quality, and significantly enhancing the value of biopharmaceutical goods. Additionally, manufacturers prioritize robust and efficient purification processes to ensure product quality and safety in light of growing outsourcing trends and the demand for biologics, which in turn enhances segmental growth. Moreover, ongoing innovations in downstream processing solutions allow biopharmaceutical companies to further drive market growth in this segment by improving process productivity, efficiency, and scalability.
Continuous Bioprocessing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Throughout the forecast period, North America is anticipated to hold the greatest share of the global market for Continuous Bioprocessing. Numerous biopharmaceutical businesses, including well-known pharmaceutical corporations, are based in North America. These businesses are pioneers in the creation and marketing of biologic medications, which fuels the need for ongoing bioprocessing technology to optimize production processes, boost output, and guarantee product quality. Furthermore, this area is proud of its strong network of academic institutions, research facilities, and biotechnology hubs that support the advancement of bioprocessing technology.
In addition, the Continuous Bioprocessing market is anticipated to expand at the fastest rate in the world during the projected period in Asia Pacific driven by factors like the growth of the biopharmaceutical sector, a rise in life sciences research, an increase in investments made by biotechnology and pharmaceutical businesses, and the expanding market for (CMOs). Companies and research institutions in Asia Pacific make significant R&D investments to create state-of-the-art bioprocessing platforms that propel continual bioprocessing improvements and help them keep a competitive edge in the worldwide market.
There are many different types of players in the dynamic and varied continuous bioprocessing sector, including Merck KGaA, Sartorius AG, and Thermo Fisher Scientific. The market is predicted to become more competitive as technology develops and the need for biopharmaceuticals rises, spurring additional innovation and market consolidation.
August 2023: To improve upstream process intensification, Sartorius and Repligen Corporation unveiled an integrated bioreactor system that combined Biostat STR and XCell ATF technology. It is anticipated that the launch will assist the business in growing both its sales revenue and product portfolio.
March 2023: Curia and Corning worked together to establish and expedite continuous-flow manufacturing and development programs for the global chemical and biopharmaceutical sectors. Through this partnership, Corning's G1 production system-which supports the use of flow-chemistry technology to produce APIs of higher quality-will be installed for the first time in the world.
July 2022: Cytiva opened a new location in Muskegon, Michigan, to expand its business. The new manufacturing facility for chromatography resins is a component of Cytiva's investment in growth.